Earnings call transcript: Personalis Q2 2025 reveals revenue miss, stock steady

Personalis Inc. (PSNL) reported mixed Q2 2025 results, with an EPS of -$0.23 slightly exceeding expectations, but revenue of $17.2 million significantly missing forecasts and declining 24% year-over-year, largely attributed to headwinds in biopharma R&D spending and project delays. Despite the revenue shortfall, shares saw a modest aftermarket increase. The company subsequently lowered its full-year revenue guidance to $70-80 million, yet emphasized robust 400% year-over-year growth in clinical revenue and strong adoption of its NextPersonal minimal residual disease (MRD) test, with management highlighting the strategic importance of securing Medicare reimbursement for two indications by year-end as a critical catalyst for future profitability.

Analysis

Personalis Inc. (PSNL) presented a mixed financial profile for Q2 2025, characterized by a conflict between near-term revenue headwinds and strong momentum in its strategic growth segments. While earnings per share of -$0.23 narrowly beat the forecast of -$0.24, total revenue of $17.2 million missed expectations by 14.3% and marked a 24% year-over-year decline. Management attributed this shortfall to industry-wide delays in biopharma R&D spending, which prompted a reduction in full-year revenue guidance to $70-80 million from a previous $80-90 million. In stark contrast, the company's clinical business is accelerating, with revenue from its minimal residual disease (MRD) tests growing 400% year-over-year and clinical test volume increasing 59% sequentially. The company's financial position remains solid with $173.2 million in cash, which management asserts is sufficient to reach cash flow breakeven. The pivotal catalyst for Personalis remains obtaining Medicare reimbursement for two cancer indications by year-end, an event expected to unlock substantial revenue and alleviate gross margin pressure, which fell to 27.6% due to the costs of unreimbursed tests.

Key Decisions for Investors

• Investors should weigh the current revenue pressure and reduced guidance from the biopharma segment against the significant growth momentum in the clinical MRD business, which represents the company's core long-term strategy.
• The primary catalyst to monitor is the company's progress toward securing Medicare reimbursement for two indications by year-end, as this is positioned as the key inflection point for revenue recognition and margin expansion.
• Given the forecasted annual cash usage of $75 million to fund clinical volume growth ahead of reimbursement, it is critical to monitor the company's balance sheet and any further shifts in biopharma project timelines.
• Consider the execution risk associated with the reimbursement timeline and competitive pressures in the MRD market, balanced against the potential upside from the Tempus partnership and the differentiated ultra-sensitive NextPersonal test.